Why the study?
Does treatment with felodipine or diltiazem affect plasma levels of MMP-2 and MMP-9 in essential hypertensive patients?
Does treatment with felodipine or diltiazem affect plasma levels of MMP-2 and MMP-9 in essential hypertensive patients?
Felodipine, but not diltiazem, increases plasma levels of MMP-2 in patients with essential hypertension, suggesting differential effects of calcium channel blockers on extracellular matrix metabolism.
Answers are grounded in this paper and cite their sources.
Felodipine may raise MMP-2 in essential hypertension; leaves open differential calcium-channel blocker effects on matrix turnover pending prospective trials.
The ability of some antihypertensive drugs to protect from vascular damage in hypertension might be partially due to their ability to control matrix metalloproteinase (MMP)-mediated extracellular matrix metabolism, which in turn may contribute to vascular remodeling. This study was designed to investigate whether treatment with felodipine or diltiazem has any effect on plasma levels of MMP-2 and MMP-9 in essential hypertensive patients. We measured plasma levels of active MMP-2 and MMP-9 in 72 hypertensive subjects and 45 controls, both before and after 6 months of treatment with felodipine (group A) or diltiazem (group B). Mean adjusted differences, before and after each treatment, for MMP-2 and MMP-9 levels were: 19.8 (P =.01) for MMP-2, 0.2 (P =.5) for MMP-9 (group A), and 1.4 (P =.4) for MMP-2, 0.2 (P =.7) for MMP-9 (group B). These findings show that MMP-2 level is raised by treatment with felodipine but not diltiazem, whereas MMP-9 is unaffected by either treatment.
No takes yet. Share an insight, caveat, or question.
A. Zervoudaki (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: